Expression of CD44s and CD44v6 in Lung Cancer and Their Correlation with Prognostic Factors
The International Journal of Biological Markers · 2011-01 · 26 (1) · 50-57
DOI: 10.5301/jbm.2011.6291 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Biological Markers, online erschienen am 13.03.2018. Verfasst von Alaa M Afify und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Pathology and Laboratory Medicine, University of California Davis Health System, Sacramento, CA 95817, USA. alaa.afify@ucdmc.uc…. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: NCRR NIH HHS.
Abstract (Originalsprache)
Background
CD44, a transmembrane glycoprotein receptor, plays a major role in tumor progression and metastasis.
Objective
To evaluate the expression of CD44 standard (CD44s) and its variant 6 (CD44v6) in normal and neoplastic lung tissue and correlate it with prognostic factors in lung cancer.
Methods
The study included 52 non-small cell lung carcinomas (NSCLC) (21 squamous cell carcinomas and 31 adenocarcinomas), 15 small cell lung carcinomas (SCLC) and 8 carcinoid tumors. Expression of CD44s and CD44v6 was evaluated by immunohistochemistry and correlated with lung cancer prognostic factors.
Results
All squamous cell carcinomas expressed both CD44s and CD44v6. Adenocarcinomas expressed CD44s in 39% of cases and CD44v6 in 45%. Carcinoid tumors expressed only CD44s in 88% of cases. All SCLCS were negative for both CD44s and CD44v6. A restricted panel consisting of CD44s and CD44v6 will discriminate NSCLC from SCLC with a sensitivity of 67% and a specificity of 100%. In adenocarcinoma CD44s expression was significantly correlated with lymph node metastases (p=0.007) while CD44v6 expression was more significantly associated with tumor size (p=0.0032).
Conclusions
CD44s and CD44v6 are expressed in certain types of lung cancer. In adenocarcinoma CD44s and CD44v6 expression is significantly correlated with lymph node metastases and tumor size.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Pathology and Laboratory Medicine, University of California Davis Health System, Sacramento, CA 95817, USA. alaa.afify@ucdmc.ucdavis.edu
Förderung
- NCRR NIH HHS
Zitieren
APA
Afify, A. M., Tate, S., Durbin-Johnson, B., Rocke, D. M., & Konia, T. (2011). Expression of CD44s and CD44v6 in Lung Cancer and Their Correlation with Prognostic Factors. The International Journal of Biological Markers, 26(1), 50-57. https://doi.org/10.5301/jbm.2011.6291
Vancouver
Afify AM, Tate S, Durbin-Johnson B, Rocke DM, Konia T. Expression of CD44s and CD44v6 in Lung Cancer and Their Correlation with Prognostic Factors. The International Journal of Biological Markers. 2011;26(1):50-57. doi:10.5301/jbm.2011.6291
BibTeX
@article{Afify2011,
author = {Afify, Alaa M and Tate, Stacey and Durbin-Johnson, Blythe and Rocke, David M and Konia, Thomas},
title = {Expression of CD44s and CD44v6 in Lung Cancer and Their Correlation with Prognostic Factors},
journal = {The International Journal of Biological Markers},
year = {2011},
volume = {26},
number = {1},
pages = {50--57},
doi = {10.5301/jbm.2011.6291}
}
EUVIMED